Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04635839 · ClinicalTrials.gov registry record · Phase 4
Heparin Prophylaxis Dosing for Antepartum Hospitalizations (HEPDOSE)
A Phase 4 study, sponsored by University of California, Los Angeles.
- Completed
- Registry status
- Phase 4
- Development phase
- 46
- Enrollment target
NCT04635839 is a Phase 4 study that has completed, run by University of California, Los Angeles. The registered enrollment target is 46 participants.
The verdict
NCT04635839, a Phase 4 study, has completed, sponsored by University of California, Los Angeles.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 46 participants
- Enrollment target
Study Summary
This study is a randomized control trial to compare gestational age-based dosing with standard dosing of unfractionated heparin for thromboprophylaxis of hospitalized antepartum patients. The investigators aim to determine the effect of dosing on receipt of neuraxial anesthesia and pregnancy outcomes and evaluate the pharmacokinetics and pharmacodynamics of unfractionated heparin in pregnancy.
Interventions
- DRUG Standard Dose of Unfractionated Heparin
- DRUG Gestational Age-Based Dose of Unfractionated Heparin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 46 participants |
| Start Date | 2020-12-15 |
| Est. Completion | 2022-05-01 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04635839
The ClinicalTrials.gov registry entry for NCT04635839 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 46 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of California, Los Angeles, which has 897 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Standard Dose of Unfractionated Heparin is the first listed.
NCT04635839 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04635839 about?
NCT04635839 is a clinical study titled "Heparin Prophylaxis Dosing for Antepartum Hospitalizations (HEPDOSE)". This study is a randomized control trial to compare gestational age-based dosing with standard dosing of unfractionated heparin for thromboprophylaxis of hospitalized antepartum patients. The investigators aim to determine the effect of dosing on receipt of neuraxial anesthesia and pregnancy outcome...
What is the current status of trial NCT04635839?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 46 participants. The study started on 2020-12-15. Estimated completion is 2022-05-01.
What interventions are being tested in trial NCT04635839?
The interventions under investigation include: Standard Dose of Unfractionated Heparin (DRUG), Gestational Age-Based Dose of Unfractionated Heparin (DRUG).
Who is sponsoring clinical trial NCT04635839?
This trial is sponsored by University of California, Los Angeles, which has 897 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.